hero background ribbon

Release Details

Verve Therapeutics CEO Sekar Kathiresan, M.D., to Give Keynote Presentation at the International Society for Stem Cell Research (ISSCR) 2020 Virtual Annual Meeting

Jun 17, 2020

CAMBRIDGE, Mass. — June 17, 2020 — Verve Therapeutics, a next-generation cardiovascular company developing medicines that safely edit the adult human genome to permanently reduce a person’s risk of coronary heart disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve Therapeutics, will give a keynote presentation on the genetic basis for risk and resistance to coronary heart disease and gene editing as a promising new treatment approach at the ISSCR 2020 Virtual Annual Meeting on Saturday, June 27, 2020.

Dr. Kathiresan’s presentation titled, “From reading the genome for risk to rewriting it for health,” will be delivered during the “Clinical Innovation & Gene Editing” plenary session. The session will begin at 4:00 p.m. ET, with the keynote address at 5:45 p.m. ET. Dr. Kathiresan will discuss the discovery of cardioprotective genetic mutations, Verve’s approach to develop one-time gene editing medicines that mimic these protective mutations to treat coronary heart disease, and Verve’s progress with new preclinical data in non-human primates. The presentation will be available for on-demand viewing by registrants immediately following the presentation through July 31, 2020.

About Verve Therapeutics
Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. The company brings together human genetics analysis and gene editing — two of the biggest breakthroughs in 21st century biomedicine — to develop transformative therapies for coronary heart disease. Verve is developing medicines, administered once in life, to safely edit the genome of adults to permanently lower LDL cholesterol and triglyceride levels, and reduce the risk of coronary heart disease and heart attack. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, Verve is backed by a top-tier syndicate of investors, including GV (formerly Google Ventures), ARCH Venture Partners, F-Prime Capital, Biomatics Capital, Wellington Management, Casdin Capital, and Partners Innovation Fund. Verve is headquartered in Cambridge, Massachusetts. For more information, visit www.VerveTx.com.


Media Contact

Gina Nugent, 617-460-3579
Ten Bridge Communications